Promising ALS drug combo enters final testing phase
Disease control
Recruiting now
This study tests whether adding masitinib to the standard ALS drug riluzole can slow the disease better than riluzole alone. About 495 adults with ALS will receive either masitinib or a placebo, plus riluzole, for up to 48 weeks. Researchers will measure changes in muscle functio…
Phase: PHASE3 • Sponsor: AB Science • Aim: Disease control
Last updated Apr 26, 2026 20:03 UTC